Corvus Pharmaceuticals Inc. (CRVS) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) Comparison side by side

Since Corvus Pharmaceuticals Inc. (NASDAQ:CRVS) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) are part of the Biotechnology industry, they are influenced by contrast. The influences particularly affect the analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership of both companies.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Corvus Pharmaceuticals Inc. N/A 0.00 48.36M -1.97 0.00
Regeneron Pharmaceuticals Inc. 6.71B 6.54 2.44B 18.46 20.46

Demonstrates Corvus Pharmaceuticals Inc. and Regeneron Pharmaceuticals Inc. earnings per share (EPS), gross revenue and valuation.


Table 2 shows the net margins, return on equity and return on assets of the two firms.

Net Margins Return on Equity Return on Assets
Corvus Pharmaceuticals Inc. 0.00% -41.3% -38%
Regeneron Pharmaceuticals Inc. 36.36% 25.9% 18.5%


The Current Ratio and Quick Ratio of Corvus Pharmaceuticals Inc. are 16.1 and 16.1 respectively. Its competitor Regeneron Pharmaceuticals Inc.’s Current Ratio is 4 and its Quick Ratio is 3.6. Corvus Pharmaceuticals Inc. can pay off short and long-term obligations better than Regeneron Pharmaceuticals Inc.

Analyst Ratings

The Recommendations and Ratings for Corvus Pharmaceuticals Inc. and Regeneron Pharmaceuticals Inc. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Corvus Pharmaceuticals Inc. 0 0 0 0.00
Regeneron Pharmaceuticals Inc. 0 3 2 2.40

Regeneron Pharmaceuticals Inc. on the other hand boasts of a $412.33 average price target and a 2.15% potential upside.

Institutional & Insider Ownership

Roughly 87.6% of Corvus Pharmaceuticals Inc. shares are held by institutional investors while 73.7% of Regeneron Pharmaceuticals Inc. are owned by institutional investors. Insiders held roughly 5.08% of Corvus Pharmaceuticals Inc.’s shares. Comparatively, Regeneron Pharmaceuticals Inc. has 0.4% of it’s share held by insiders.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Corvus Pharmaceuticals Inc. -2.68% -26.33% -45.35% -54.81% -45.51% -43.82%
Regeneron Pharmaceuticals Inc. 3.27% 3.66% -4.42% 21.04% 1.07% 0.43%

For the past year Corvus Pharmaceuticals Inc. has -43.82% weaker performance while Regeneron Pharmaceuticals Inc. has 0.43% stronger performance.


On 10 of the 11 factors Regeneron Pharmaceuticals Inc. beats Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint. The company is also developing an anti-CD73 monoclonal antibody that inhibits the production of adenosine; an antagonist of the adenosine A2B receptor; and small molecule covalent inhibitors of interleukin-2 inducible kinase. Corvus Pharmaceuticals, Inc. was founded in 2014 and is based in Burlingame, California.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Its products include EYLEA injection for the treatment of neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion; Praluent injection, an adjunct to diet and tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and ARCALYST injection for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and childrenÂ’s. It also markets Kevzara injection for the treatment of rheumatoid arthritis in adults; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer. The company also develops EYLEA, trap-based clinical product that is in Phase III study for the treatment of neovascular glaucoma. Regeneron Pharmaceuticals, Inc. has collaboration agreement with Sanofi for the development of antibody-based clinical products comprising Praluent, Sarilumab, Dupixent, REGN2810, REGN3500, and REGN3767; Bayer HealthCare LLC for the development of Nesvacumab/aflibercept, which is used in ophthalmology; and with Teva and Mitsubishi Tanabe Pharma Corporation for developing Fasinumab, an antibody to nerve growth factor. It also has collaboration agreements with Intellia Therapeutics, Inc. to advance CRISPR/Cas gene-editing technology for in vivo therapeutic development; and the U.S. Department of Health and Human Services to develop treatments combating infectious diseases. The company was founded in 1988 and is headquartered in Tarrytown, New York.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.